10-Q: OSR Health Reports Q2 2026 Results, Faces Liquidity Challenges

OSR Health, Inc. reported a net loss of $1.0 million for Q2 2026, with significant decreases in net sales and ongoing operational losses, while also highlighting efforts to secure additional capital.

Summary

• OSR Health, Inc. reported a net loss of $1,004,038 for the three months ended June 30, 2026, compared to a net loss of $5,225,198 for the same period in 2025.
• For the six months ended June 30, 2026, the net loss was $4,471,212, an improvement from $16,618,012 in the prior year.
• Net sales decreased significantly by 72% to $315,669 for Q2 2026 and by 58% to $799,727 for the first half of 2026, primarily due to changes in RMC's contractual arrangements.
• Selling, general, and administrative (SG&A) expenses decreased by 41% for Q2 2026 and 17% for the first half of 2026, largely due to a reduction in one-time costs associated with the business combination.
• The company had cash and cash equivalents of $1,499,603 as of June 30, 2026, and an accumulated deficit of $40,950,247.
• OSR Health continues to rely on equity financing, having raised $3.38 million through an equity line of credit (ELOC) and exploring other financing initiatives.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant net losses, a substantial accumulated deficit, and ongoing concerns about liquidity and the need for continuous capital raises, despite some operational improvements.

Positives

• Gross profit margin improved significantly, from approximately 3% in Q2 2025 to 27% in Q2 2026, and from 11% in H1 2025 to 31% in H1 2026, driven by a shift to a consignment-based arrangement for RMC.
• Operating loss decreased by 42% to $3,032,915 for Q2 2026 and by 18% to $6,700,098 for the first half of 2026.
• Net loss for the six months ended June 30, 2026, showed a substantial improvement, decreasing to $4,471,212 from $16,618,012 in the prior year.
• The company successfully acquired Woori-IO Co., Ltd. in January 2026, expanding its portfolio into non-invasive biosensing technologies for glucose monitoring.

Negatives

• Net sales experienced a sharp decline of 72% in Q2 2026 and 58% in the first half of 2026.
• The company has a substantial accumulated deficit of $40,950,247 as of June 30, 2026.
• Cash and cash equivalents stood at $1,499,603 as of June 30, 2026, indicating a tight liquidity position.
• The company has material weaknesses in its internal control over financial reporting that have not been fully remediated.
• The company is subject to ongoing litigation, including a breach of contract claim from Chardan Capital Markets, LLC.

Risks

• The company has experienced significant operating losses and negative cash flows from operating activities since its inception.
• The company has an urgent need for additional capital and relies heavily on equity financing, such as the ELOC, which can lead to dilution.
• The company's ability to continue as a going concern is dependent on its ability to secure additional financing and achieve profitability.
• The company faces risks related to its ongoing business combinations and acquisitions, including integration challenges and potential impairments.
• The company is subject to market risks, including currency fluctuations and interest rate changes, although it states it has no financial instruments subject to variable interest rates.
• The company has material weaknesses in internal control over financial reporting, which could lead to errors in financial reporting.

Future Outlook

OSR Health expects to continue utilizing its equity line of credit (ELOC) until the end of its commitment period (December 31, 2026), while also planning to implement less dilutive financing facilities like an At-the-Market (ATM) offering. The company anticipates incurring significant R&D expenses, estimated between $2.5 million to $3.0 million per quarter, potentially increasing to $5.0 million to $6.0 million per quarter in the future, contingent on successful financing.

Management Comments

• The company has experienced difficulties in securing R&D-related funding, but expects to incur significant R&D expenses if financing efforts progress successfully.
• The company intends to exercise a higher level of prudence and control in the execution of the ELOC to minimize dilution and price impact.
• Management concluded that material weaknesses in internal control over financial reporting existed as of December 31, 2025, and these have not been fully remediated as of June 30, 2026.

Industry Context

StockSavvy.ai notes that OSR Health operates in the competitive healthcare sector, focusing on diverse areas like oral immunotherapies, biologics, medical device distribution, and biosensing technologies. The company's strategy involves acquiring and developing innovative healthcare companies globally. The reported financial results, particularly the decline in net sales and ongoing losses, are common challenges for early-stage or acquisitive healthcare companies that require substantial R&D investment and capital.

Comparison to Industry Standards

• The gross profit margin improvement from 3% to 27% (Q2) and 11% to 31% (H1) due to a change in revenue recognition model (consignment vs. purchase-resale) is a significant operational shift, but the underlying net sales decline indicates challenges in market demand or sales strategy for RMC.
• The substantial decrease in SG&A expenses (41% in Q2, 17% in H1) is positive, but the report attributes this partly to the absence of one-time business combination costs in the current period, making direct comparison difficult.
• The company's reliance on equity financing (ELOC) and the resulting dilution are common in the biotech and healthcare sectors where R&D is capital-intensive and profitability is often long-term, but it contrasts with more established companies that may rely on debt or operating cash flow for funding.
• The reported net loss and accumulated deficit are significant, but not entirely uncommon for companies in the development or acquisition phase within the healthcare industry, which often requires substantial upfront investment before revenue generation.

Corporate Governance

Legal Proceedings

• Civil action filed by Benjamin Securities, Inc., seeking $425,000.00 in brokerage fees and costs, pending as of March 31, 2026.
• Complaint filed by Chardan Capital Markets, LLC, asserting claims for breach of contract and related causes of action; parties are currently engaged in settlement discussions while discovery proceeds.

Related Party Transactions

• Short-term borrowings include balances with BCM Europe AG ($860,000), Bellevue Global Life Sciences Investors LLP ($1,207,464), and individuals ($1,276,030) as of June 30, 2026.
• The company has an agreement to pay an affiliate of Bellevue Capital Management, LLC a monthly fee of $7,500 for office space, utilities, and administrative support.

Stakeholder Impact

• Shareholders may experience dilution due to ongoing equity financing activities, including the use of the ELOC and planned ATM offerings.
• Investors may be concerned about the company's continued net losses, accumulated deficit, and material weaknesses in internal controls.
• Creditors and lenders may face increased risk given the company's reliance on external financing and ongoing liquidity concerns.

Next Steps

• Continue to utilize the ELOC until December 31, 2026, with increased prudence to minimize dilution.
• Implement new, less dilutive equity financing facilities such as an ATM offering.
• Secure additional financing to fund operations, R&D expenses, and general corporate purposes.
• Remediate material weaknesses in internal control over financial reporting.
• Continue settlement discussions for the lawsuit filed by Chardan Capital Markets, LLC.

Key Dates

Recommendation

The company exhibits significant financial distress with declining revenues, substantial accumulated deficits, and ongoing operating losses. While there are efforts to improve margins and secure capital, the reliance on dilutive equity financing, material weaknesses in internal controls, and pending litigation present considerable risks. The current financial trajectory and operational challenges suggest a negative outlook for the stock in the near to medium term.

Keywords

OSR Health, Form 10-Q, Quarterly Report, Financial Statements, Results of Operations, Business Combination, Equity Financing, Liquidity